ASCO will grade drugs

Share this article:

The American Society of Clinical Oncology is taking notes. BioCentury reports that the professional society is grading cancer drugs based on benefit, toxicity and cost.

Chief Medical Officer Richard Schilsky told BioCentury that the scorecard is necessary because the price of a drug does not always reflect its impact.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.